Rhythm Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of peptide therapeutics for the treatment of rare genetic disorders of obesity in the United States. Its peptide candidates include Setmelanotide, a melanocortin-4 receptor agonist, which is in Phase III clinical trial to treat POMC and leptin receptor deficiency obesity; and Phase II clinical trial for Bardet-Biedl and Alström syndrome, POMC heterozygous deficiency obesity, and POMC epigenetic disorders. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. Rhythm Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts. Rhythm Pharmaceuticals, Inc. is a subsidiary of Motus Therapeutics, Inc.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:RYTM
CUSIPN/A
Phone857-264-4280
Debt
Debt-to-Equity RatioN/A
Current Ratio40.16
Quick Ratio40.16
Price-To-Earnings
Trailing P/E Ratio-10.03
Forward P/E Ratio-14.45
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$5.31 per share
Price / Book5.28
Profitability
EPS (Most Recent Fiscal Year)($2.83)
Net Income$-33,700,000.00
Net MarginsN/A
Return on Equity-41.44%
Return on Assets-34.27%
Miscellaneous
Employees26
Outstanding Shares34,170,000
Market Cap$996.89 million
Rhythm Pharmaceuticals (NASDAQ:RYTM) Frequently Asked Questions
What is Rhythm Pharmaceuticals' stock symbol?
Rhythm Pharmaceuticals trades on the NASDAQ under the ticker symbol "RYTM."
How were Rhythm Pharmaceuticals' earnings last quarter?
Rhythm Pharmaceuticals Inc (NASDAQ:RYTM) posted its quarterly earnings results on Wednesday, August, 8th. The company reported ($0.52) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.48) by $0.04. View Rhythm Pharmaceuticals' Earnings History.
When is Rhythm Pharmaceuticals' next earnings date?
What price target have analysts set for RYTM?
5 brokers have issued twelve-month price objectives for Rhythm Pharmaceuticals' shares. Their predictions range from $30.00 to $42.00. On average, they anticipate Rhythm Pharmaceuticals' stock price to reach $37.20 in the next year. This suggests a possible upside of 32.7% from the stock's current price. View Analyst Price Targets for Rhythm Pharmaceuticals.
What is the consensus analysts' recommendation for Rhythm Pharmaceuticals?
5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Rhythm Pharmaceuticals in the last year. There are currently 1 hold rating and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Rhythm Pharmaceuticals.
What are Wall Street analysts saying about Rhythm Pharmaceuticals stock?
Here are some recent quotes from research analysts about Rhythm Pharmaceuticals stock:
- 1. According to Zacks Investment Research, "Rhythm Pharmaceuticals, Inc. is a biopharmaceutical company. It focused on the development and commercialization of peptide therapeutics for the treatment of rare genetic deficiencies which result in life-threatening metabolic disorders. The Company's product candidate principally consists of setmelanotide, a potent, first-in-class melanocortin-4 receptor or MC4R, agonist for the treatment of rare genetic disorders of obesity. Rhythm Pharmaceuticals, Inc. is based in Boston, MA. " (8/15/2018)
- 2. Needham & Company LLC analysts commented, "We hosted a series of mtgs with mgmt and investors last wk. Enrollment in setmelanotide Phase 3 trial in POMC patients is nearing completion. Mgmt did not disclose current enrollment figure, but did reiterate guidance for completion in 1H18. Phase 3 trial in LepR patients has been initiated. Mgmt still expects to complete enrollment of this latter trial by YE18, noting help from an overlap in sites w/ POMC trial and higher prevalence. A mtg w/ FDA to discuss Bardet-Biedl Phase 3 design is scheduled. Trial likely to be somewhat larger, but it is not yet clear whether a placebo arm will be needed. We expect initial data from Phase 2 testing in Alstrom, Epigenetic POMC, and possibly Heterozygous POMC patients in 1H18. Mgmt did not guide on timing for an update on Bardet-Biedl Phase 2 trial, but did convey a bias towards expectations for a more profound impact on weight loss w/ longer duration treatment. Reiterate BUY. We believe Phase 2 POMC and LepR data are compelling and have high conviction around positive Phase 3 outcomes in 2019. We believe stock has room for upside around positive Phase 2 trial updates in 1H19, which would expand peak sales potential." (2/26/2018)
- 3. Cowen Inc analysts commented, "Rhythm released Q3 financials this morning, following the presentation of promising." (11/14/2017)
Are investors shorting Rhythm Pharmaceuticals?
Rhythm Pharmaceuticals saw a increase in short interest in September. As of September 28th, there was short interest totalling 1,351,415 shares, an increase of 44.2% from the September 14th total of 937,240 shares. Based on an average daily trading volume, of 366,595 shares, the short-interest ratio is currently 3.7 days. Currently, 7.3% of the shares of the stock are sold short. View Rhythm Pharmaceuticals' Current Options Chain.
Who are some of Rhythm Pharmaceuticals' key competitors?
Some companies that are related to Rhythm Pharmaceuticals include Taro Pharmaceutical Industries (TARO), Ultragenyx Pharmaceutical (RARE), Endo International (ENDP), Intercept Pharmaceuticals (ICPT), Blueprint Medicines (BPMC), Emergent Biosolutions (EBS), Madrigal Pharmaceuticals (MDGL), Horizon Pharma (HZNP), Array Biopharma (ARRY), Evotec (EVTCY), Akcea Therapeutics (AKCA), Ascendis Pharma A/S (ASND), Ironwood Pharmaceuticals (IRWD), Supernus Pharmaceuticals (SUPN) and Myokardia (MYOK).
Who are Rhythm Pharmaceuticals' key executives?
Rhythm Pharmaceuticals' management team includes the folowing people:
- Dr. Keith Michael Gottesdiener, Pres, CEO & Director (Age 64)
- Mr. Hunter C. Smith, CFO & Treasurer (Age 49)
- Ms. Nithya Desikan, Chief Commercial Officer (Age 39)
- Mr. Leonardus H.T. van der Ploeg, Chief Scientific Officer (Age 63)
- Mr. Simon D. Kelner, Chief HR Officer (Age 45)
When did Rhythm Pharmaceuticals IPO?
(RYTM) raised $100 million in an IPO on Thursday, October 5th 2017. The company issued 6,700,000 shares at a price of $14.00-$16.00 per share. Morgan Stanley, BofA Merrill Lynch and Cowen served as the underwriters for the IPO and Needham was co-manager.
How do I buy shares of Rhythm Pharmaceuticals?
Shares of RYTM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Rhythm Pharmaceuticals' stock price today?
One share of RYTM stock can currently be purchased for approximately $28.04.
How big of a company is Rhythm Pharmaceuticals?
Rhythm Pharmaceuticals has a market capitalization of $996.89 million. The company earns $-33,700,000.00 in net income (profit) each year or ($2.83) on an earnings per share basis. Rhythm Pharmaceuticals employs 26 workers across the globe.
What is Rhythm Pharmaceuticals' official website?
How can I contact Rhythm Pharmaceuticals?
Rhythm Pharmaceuticals' mailing address is 500 BOYLSTON STREET 11TH FLOOR, BOSTON MA, 02116. The company can be reached via phone at 857-264-4280 or via email at [email protected]
MarketBeat Community Rating for Rhythm Pharmaceuticals (NASDAQ RYTM)
MarketBeat's community ratings are surveys of what our community members think about Rhythm Pharmaceuticals and other stocks. Vote "Outperform" if you believe RYTM will outperform the S&P 500 over the long term. Vote "Underperform" if you believe RYTM will underperform the S&P 500 over the long term. You may vote once every thirty days.
